Compare VRA & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRA | QTTB |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.9M | 97.5M |
| IPO Year | 2010 | 2018 |
| Metric | VRA | QTTB |
|---|---|---|
| Price | $3.95 | $13.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 449.1K | ★ 587.1K |
| Earning Date | 06-10-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.47 | ★ 136.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $416,097,000.00 | $53,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $1.40 |
| 52 Week High | $4.39 | $14.85 |
| Indicator | VRA | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 59.88 | 60.89 |
| Support Level | $2.17 | $4.93 |
| Resistance Level | $4.37 | $14.85 |
| Average True Range (ATR) | 0.32 | 1.37 |
| MACD | 0.06 | -0.26 |
| Stochastic Oscillator | 69.81 | 74.13 |
Vera Bradley Inc designs women's handbags, luggage, and travel items, fashion and home accessories, and gifts. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct and Vera Bradley Indirect.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).